Published in Nutraingredients Europe –https://www.nutraingredients.com/Product-innovations/Somin-On-for-cognition-The-power-of-Sominone-for-enhanced-cognitive-health/

Somin-On the world’s first branded ingredient standardised with Sominone, from Ashwagandha plant developed to elevate cognitive performance and support attention visual information processing learning, spatial memory, visuo- spatial memory skills, verbal skill memory, working memory , memory acquisition, memory retention and accuracy, immediate memory, recall and orientation.

Here is why Somin-On is your trusted choice.

– Innovative standardization – Somin-On is standardized to contain NLT 2% Somin-On, ensuring optimal efficacy for cognitive enhancement.

– Unmatched Quality assurance: Somin-On is supported by international studies demonstrating its safety and reliability.

– Scientifically Validated: Somin-On is supported by human studies demonstrating its safety and reliability.

What is Sominone?
Sominone is a molecule derived from Withania somnifera, commonly known as Ashwagandha, a revered adaptogenic herb in Ayurvedic medicine. Sominone is a specific, bioactive withanolide metabolite that has been identified through rigorous pharmacological screening and scientific validation as the principal neuroactive constituent responsible for Ashwagandha’s cognitive-enhancing effects.

Cognitive decline is a growing concern in aging populations, often beginning with subtle issues in memory, learning, attention, and problem-solving.

These early signs, known as Mild Cognitive Impairment (MCI), mark the transition between normal aging and more serious conditions like Alzheimer’s and other dementias.

SominOn™ is uniquely standardized to contain a minimum of 2% sominone. While traditional Ashwagandha ingredients often specify their potency based on “total withanolide content“, SominOn™ adopts a precision-standardization approach. Sominone is a biologically active metabolite of Withanoside IV. It is a pharmacologically validated molecule that directly correlates with observed neurocognitive benefits in preclinical and clinical studies. SominOn™ was developed through a deep understanding of neurobiology and phytochemistry, with the primary goal of addressing the growing global burden of mild cognitive impairment
(MCI), a condition often considered a transitional stage between normal aging and dementia, particularly Alzheimer’s.